What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

Original reporting
Published Nov 3, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

For RXRX, the combination of (1) clinical readouts and dose selection for REC-1245, (2) FDA discussion and planned registrational-study start timing, and (3) quantified cash and expense guidance into 2029 creates a multi-pronged catalyst set that can shift near-term positioning.

02

Market read

Traders can reassess RXRX’s pipeline risk and financing durability based on disclosed REC-1245 dose/tolerability details, FDA study-planning timeline, and the $200M follow-on plus 2026-2027 cash expense guidance.

03

What to watch

The FDA registrational-study timeline is contingent on regulatory alignment, and the most decision-critical endpoints are still slated for 2027, leaving near-term valuation sensitive to interim updates and partner execution.

Relevance 8/10Novelty 7/10Timing: post-Q3 call, positioning for 2027 registrational and expansion-cohort data

Background

The piece summarizes Recursion Pharmaceuticals’ Q3 earnings call, covering GI polyp burden data, REC-1245 Phase I updates, partnership milestones, and financing/cash runway guidance.

Company-level read

Ticker impact

$RXRXBullishMedium confidence
Context

Recursion reported Q3 call updates including REC-1245 Phase I response rates, FDA discussion for a registrational GI study, and a $200M oversubscribed follow-on offering.

Expected impact

Likely upward bias as investors price in improved pipeline signals and extended runway, tempered by dose-limiting toxicity at higher REC-1245 dose.

Evidence & confidence

The article discloses multiple decision-relevant items: REC-1245 expansion dose selection with no DLT at 45 mg, higher-dose DLTs, FDA study design discussions, and quantified financing and expense guidance into 2029.

Market effects

Reinforces investor focus on AI-enabled biotech platforms translating into early clinical signals and partner-funded development.

Primarily US biotech sentiment, with potential spillover to healthcare growth/biotech risk appetite.

Partnership milestones with Sanofi and Roche Genentech highlight continued global pharma interest in platform-driven discovery.

Counterpoint

Early Phase I response and disease control can be noisy; the higher-dose cohort showed DLTs, so efficacy versus tolerability may not translate cleanly into registrational success.

Key entities

  • Recursion Pharmaceuticals

    NASDAQ-listed biotech whose Q3 call covered GI program updates, REC-1245 Phase I results, partnership milestones, and follow-on financing/cash runway.

  • Sanofi

    Exercised an option on a potential first-in-class oral small-molecule candidate; triggered a $10M payment and future milestones/royalties.

  • Roche Genentech

    Optioned a neuroscience target from Recursion’s biology maps; discovery underway.

  • FDA

    Discussed registrational-study design with Recursion for a GI program, with targeted start in 2H 2027 subject to alignment.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.